Physician profile
Saul Amber
NPI 1609921915
$3,998.21
in general payments reported to CMS, 2019-2025
26 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $296 · 2021: $607 · 2022: $628 · 2023: $344 · 2024: $1,150 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $898.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $642.37 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $455.89 | 2022-2025 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $395.42 | 2019-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $329.57 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Impulse Dynamics (USA) INC. | $231.26 | 2022-2024 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $184.26 | 2024 | |
| Globus Medical, INC. | $139.50 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.53 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.39 | 2022 | |
| Amgen INC. | $102.09 | 2020-2025 | Repatha, Otezla, Repatha |
| Lucid Diagnostics INC. | $94.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.05 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $30.89 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $29.87 | 2023 | Nuedexta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $24.79 | 2021 | |
| Pfizer INC. | $23.66 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $22.75 | 2023 | Austedo |
| Dexcom, INC. | $22.24 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $19.98 | 2025 | Veozah |
| Renalytix Ai, INC. | $18.75 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $16.17 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $15.92 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $15.89 | 2022 | |
| Glaxosmithkline, LLC. | $13.41 | 2020 | |
| Optos, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Amber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.